TCM combined with EGFR-TKIs significantly improves progression-free survival in advanced EGFR-mutant NSCLC
Traditional Chinese medicine may improve survival for certain lung cancers
This meta-analysis evaluates the impact of traditional Chinese medicine (TCM) combined with EGFR-TKIs in patients with advanced EGFR-mutant …
Combining traditional Chinese medicine with targeted therapies may help patients with a specific type of lung cancer live longer without the…
EGFR-TKI plus anti-angiogenic therapy shows HR 0.63 for overall survival in NSCLC with brain metastases
Combination therapies show promise for lung cancer with brain spread
This systematic review and network meta-analysis of 5432 patients with EGFR-mutated non-small cell lung cancer and brain metastases found th…
New data suggests that combining specific drugs can improve survival and slow cancer growth in patients with lung cancer that has spread to …
Advanced-stage NSCLC patients show higher objective response rates than early-stage patients on EGFR-TKI monotherapy
EGFR-TKIs Work Differently by Lung Cancer Stage
This meta-analysis of 3713 patients compared the efficacy and safety of EGFR-TKIs in early-stage versus advanced-stage non-small cell lung c…
Advanced lung cancer responds better to EGFR-TKIs, but early-stage has fewer side effects. New analysis of 3,713 patients shows stage matter…
Statin use and EGFR-TKI efficacy in EGFR-mutant non-small cell lung cancer remains to be evaluated
Statins may boost lung cancer treatment, review planned
This protocol for a systematic review and meta-analysis aims to evaluate if statin exposure is associated with improved outcomes in patients…
A new review will examine if statins improve survival in EGFR-mutant lung cancer patients on targeted therapy.
Narrative review discusses osimertinib use in EGFR-mutated NSCLC patients with TKI resistance
Osimertinib may help some lung cancer patients after resistance develops
This narrative review examines the use of osimertinib and other EGFR-TKIs in non-small cell lung cancer patients harboring EGFR mutations af…
A review suggests osimertinib could be an option for non-small cell lung cancer patients with EGFR mutations who develop resistance to earli…